Division of Nephrology and Hypertension, Department of Medicine, University of California San Diego, San Diego, CA; Imperial Valley Family Care Medical Group, El Centro, CA.
Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC.
Am J Kidney Dis. 2019 Jan;73(1):21-30. doi: 10.1053/j.ajkd.2018.07.015. Epub 2018 Oct 2.
Random assignment to the intensive systolic blood pressure (SBP) arm (<120mmHg) in the Systolic Blood Pressure Intervention Trial (SPRINT) resulted in more rapid declines in estimated glomerular filtration rates (eGFRs) than in the standard arm (SBP<140mmHg). Whether this change reflects hemodynamic effects or accelerated intrinsic kidney damage is unknown.
Longitudinal subgroup analysis of clinical trial participants.
SETTINGS & PARTICIPANTS: Random sample of SPRINT participants with prevalent chronic kidney disease (CKD) defined as eGFR<60mL/min/1.73m by the CKD-EPI (CKD Epidemiology Collaboration) creatinine-cystatin C equation at baseline.
OUTCOMES & MEASUREMENTS: Urine biomarkers of tubule function (β-microglobulin [B2M], α-microglobulin [A1M]), and uromodulin), injury (interleukin 18, kidney injury molecule 1, and neutrophil gelatinase-associated lipocalin), inflammation (monocyte chemoattractant protein 1), and repair (human cartilage glycoprotein 40) at baseline, year 1, and year 4. Biomarkers were indexed to urine creatinine concentration and changes between arms were evaluated using mixed-effects linear models and an intention-to-treat approach.
978 SPRINT participants (519 in the intensive and 459 in the standard arm) with prevalent CKD were included. Mean age was 72±9 years and eGFR was 46.1±9.4mL/min/1.73m at baseline. Clinical characteristics, eGFR, urinary albumin-creatinine ratio, and all 8 biomarker values were similar across arms at baseline. Compared to the standard arm, eGFR was lower by 2.9 and 3.3mL/min/1.73m in the intensive arm at year 1 and year 4. None of the 8 tubule marker levels was higher in the intensive arm compared to the standard arm at year 1 or year 4. Two tubule function markers (B2M and A1M) were 29% (95% CI, 10%-43%) and 24% (95% CI, 10%-36%) lower at year 1 in the intensive versus standard arm, respectively.
Exclusion of persons with diabetes, and few participants had advanced CKD.
Among participants with CKD in SPRINT, random assignment to the intensive SBP arm did not increase any levels of 8 urine biomarkers of tubule cell damage despite loss of eGFR. These findings support the hypothesis that eGFR declines in the intensive arm of SPRINT predominantly reflect hemodynamic changes rather than intrinsic damage to kidney tubule cells.
在收缩压干预试验(SPRINT)中,将患者随机分配至强化收缩压(SBP)组(<120mmHg),与标准组(SBP<140mmHg)相比,估算肾小球滤过率(eGFR)下降更快。但尚不清楚这种变化是反映了血流动力学效应还是加速了固有肾脏损伤。
临床试验参与者的纵向亚组分析。
SPRINT 中基线时通过 CKD-EPI(慢性肾脏病流行病学合作)肌酐-胱抑素 C 方程定义为 eGFR<60mL/min/1.73m2 的慢性肾脏病(CKD)患者的随机样本。
基线时、第 1 年和第 4 年时尿液中肾小管功能(β-微球蛋白[B2M]、α-微球蛋白[A1M])、尿调蛋白)、损伤(白细胞介素 18、肾损伤分子 1 和中性粒细胞明胶酶相关脂质运载蛋白)、炎症(单核细胞趋化蛋白 1)和修复(人软骨糖蛋白 40)的生物标志物。通过混合效应线性模型和意向治疗方法,根据尿液肌酐浓度对生物标志物进行指数化,并评估组间变化。
纳入了 978 名 SPRINT 参与者(强化组 519 名,标准组 459 名),其中 CKD 患者平均年龄为 72±9 岁,基线时 eGFR 为 46.1±9.4mL/min/1.73m2。基线时,两组间临床特征、eGFR、尿白蛋白/肌酐比值和 8 种生物标志物值相似。与标准组相比,强化组在第 1 年和第 4 年时 eGFR 分别低 2.9 和 3.3mL/min/1.73m2。与标准组相比,强化组在第 1 年和第 4 年时,没有任何 8 种肾小管标志物水平升高。两种肾小管功能标志物(B2M 和 A1M)在强化组分别降低了 29%(95%CI,10%-43%)和 24%(95%CI,10%-36%)。
排除了糖尿病患者,且仅有少数参与者患有晚期 CKD。
在 SPRINT 的 CKD 患者中,尽管 eGFR 下降,但随机分配至强化 SBP 组并未增加 8 种尿液肾小管细胞损伤生物标志物的任何水平。这些发现支持这样一种假说,即 SPRINT 强化组中 eGFR 的下降主要反映了血流动力学的变化,而不是肾脏肾小管细胞的固有损伤。